Degrader of MTH1 fusion proteins for use within the aTAG system
aTAG 2139 is a degrader of MTH1 fusion proteins for use within the aTAG system. Comprises a ligand selective for MTH1, a linker and the cereblon-binding ligand Thalidomide (Cat. No. 0652). Induces highly potent and selective degradation of fusion proteins after a 4 h incubation (DC50 = 0.27 nM; Dmax = 92.1%). Cell-permeable. Suitable for in vitro and in vivo applications.
Negative control aTAG 2139-NEG (Cat. No. 7575) also available.
Mouse DMPK properties are provided in the supplementary file (see below).
MTH1 can be expressed as a fusion with a target protein of interest using genome engineering techniques via CRISPR-mediated locus-specific knock-in. See protocol for more information.
| Marque | Tocris |
|---|---|
| Réf. B-LABO | BL-RE-126055 |
| Réf. fabricant | 18726366 |
| Nom chimique ou matériau | 6-(6-((4-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)butyl)carbamoyl)pyridin-3-yl)-N-methyl-4-(phenylamino)quinoline-3-carboxamide |
| CAS | 2387510-81-6 |
| Quantité | 5 mg |
| Cible | TAG Degradation Platforms |
| Formule moléculaire | C<sub>42</sub>H<sub>38</sub>N<sub>8</sub>O<sub>8</sub> |
| Pureté | 98% |
